Frequency, Outcomes, and Associated Factors for Opioid-Induced Neurotoxicity in Patients with Advanced Cancer Receiving Opioids in Inpatient Palliative Care

Overview

Journal J Palliat Med

Specialty Critical Care

Date 2018 Sep 28

PMID 30260731

Citations 11

Authors

Kyu-Hyoung Lim

Nhu-Nhu Nguyen

Yu Qian

Janet L Williams

Diane D Lui

Eduardo Bruera

Sriram Yennurajalingam

Affiliations

Soon will be listed here.

Abstract

Opioid-induced neurotoxicity (OIN) is an underdiagnosed yet distressing symptom in palliative care patients receiving opioids. However, there have been only a limited number of studies on OIN. Our aim was to determine the frequency of and risk factors for OIN in patients receiving opioids during inpatient palliative care. We randomly selected 390 of 3014 eligible patients who had undergone palliative care consultations from January 2014 to December 2014. Delirium, drowsiness, hallucinations, myoclonus, seizures, and hyperalgesia were defined as OIN and were recorded. The other 10 common symptoms in cancer patients were assessed using the Edmonton Symptom Assessment Scale (ESAS). Patient demographics, morphine equivalent daily dose (MEDD), comorbidities, OIN management, and overall survival (OS) duration were also assessed. The associations between the incidence of OIN and MEDD, the other 10 symptoms, and OS were analyzed. Fifty-seven (15%) patients had OIN. The most common symptom was delirium ( = 27). On multivariate analysis, a high MEDD ( = 0.020), high ESAS pain score ( = 0.043), drowsiness ( = 0.007), and a poor appetite ( = 0.014) were significantly associated with OIN. OIN was not significantly associated with a shorter OS duration ( = 0.80). OIN was seen in 15% of patients receiving opioids as part of inpatient palliative care. Although OIN was not associated with OS, routine monitoring is especially needed in cancer patients.

Citing Articles

Assessment of Epidemiological Data and Surveillance in Korea Substance Use Research: Insights and Future Directions.

Sung M, Rees V, Lee H, Jalali M J Prev Med Public Health. 2024; 57(4):307-318.

PMID: 38938049 PMC: 11309831. DOI: 10.3961/jpmph.24.171.

Comparison of Symptom Severity and Progression in Advanced Cancer Patients Among Different Care Settings: A Secondary Analysis.

Shiraishi R, Kizawa Y, Mori M, Maeda I, Hatano Y, Ishiki H Palliat Med Rep. 2023; 4(1):139-149.

PMID: 37360680 PMC: 10288302. DOI: 10.1089/pmr.2023.0011.

Identifying risk factors for opioid-induced neurotoxicity in cancer patients receiving oxycodone.

Omoto T, Asaka J, Nihei S, Kudo K Support Care Cancer. 2023; 31(4):208.

PMID: 36907927 DOI: 10.1007/s00520-023-07676-9.

Nicotine withdrawal as an unusual cause of terminal delirium.

Gallagher R, Williscroft D Can Fam Physician. 2022; 68(8):591-593.

PMID: 35961719 PMC: 9374075. DOI: 10.46747/cfp.6808591.

Management of Physical Symptoms in Patients with Advanced Cancer during the Last Weeks and Days of Life.

Azhar A, Hui D Cancer Res Treat. 2022; 54(3):661-670.

PMID: 35790195 PMC: 9296923. DOI: 10.4143/crt.2022.143.

References

Massie M, Holland J, Glass E . Delirium in terminally ill cancer patients. Am J Psychiatry. 1983; 140(8):1048-50. DOI: 10.1176/ajp.140.8.1048. View

Oosten A, Oldenmenger W, Mathijssen R, van der Rijt C . A Systematic Review of Prospective Studies Reporting Adverse Events of Commonly Used Opioids for Cancer-Related Pain: A Call for the Use of Standardized Outcome Measures. J Pain. 2015; 16(10):935-46. DOI: 10.1016/j.jpain.2015.05.006. View

Carvajal A, Centeno C, Watson R, Bruera E . A comprehensive study of psychometric properties of the Edmonton Symptom Assessment System (ESAS) in Spanish advanced cancer patients. Eur J Cancer. 2011; 47(12):1863-72. DOI: 10.1016/j.ejca.2011.03.027. View

Koizumi W, Toma H, Watanabe K, Katayama K, Kawahara M, Matsui K . Efficacy and tolerability of cancer pain management with controlled-release oxycodone tablets in opioid-naive cancer pain patients, starting with 5 mg tablets. Jpn J Clin Oncol. 2004; 34(10):608-14. DOI: 10.1093/jjco/hyh104. View

Kullgren J, Le V, Wheeler W . Incidence of hydromorphone-induced neuroexcitation in hospice patients. J Palliat Med. 2013; 16(10):1205-9. DOI: 10.1089/jpm.2012.0467. View

Thwaites D, McCann S, Broderick P . Hydromorphone neuroexcitation. J Palliat Med. 2004; 7(4):545-50. DOI: 10.1089/jpm.2004.7.545. View

Fine P, Portenoy R . Establishing "best practices" for opioid rotation: conclusions of an expert panel. J Pain Symptom Manage. 2009; 38(3):418-25. PMC: 4065110. DOI: 10.1016/j.jpainsymman.2009.06.002. View

Bruera E, Kuehn N, Miller M, Selmser P, Macmillan K . The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care. 1991; 7(2):6-9. View

Koroukian S . Assessing the effectiveness of Medicaid in breast and cervical cancer prevention. J Public Health Manag Pract. 2003; 9(4):306-14. DOI: 10.1097/00124784-200307000-00009. View

10.

de Stoutz N, Bruera E, Suarez-Almazor M . Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage. 1995; 10(5):378-84. DOI: 10.1016/0885-3924(95)90924-c. View

11.

Lawlor P, Gagnon B, Mancini I, Pereira J, Hanson J, Suarez-Almazor M . Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. Arch Intern Med. 2000; 160(6):786-94. DOI: 10.1001/archinte.160.6.786. View

12.

Pan H, Zhang Z, Zhang Y, Xu N, Lu L, Dou C . Efficacy and tolerability of oxycodone hydrochloride controlled-release tablets in moderate to severe cancer pain. Clin Drug Investig. 2007; 27(4):259-67. DOI: 10.2165/00044011-200727040-00005. View

13.

Breitbart W, Rosenfeld B, Roth A, Smith M, Cohen K, Passik S . The Memorial Delirium Assessment Scale. J Pain Symptom Manage. 1997; 13(3):128-37. DOI: 10.1016/s0885-3924(96)00316-8. View

14.

Daeninck P, Bruera E . Opioid use in cancer pain. Is a more liberal approach enhancing toxicity?. Acta Anaesthesiol Scand. 1999; 43(9):924-38. DOI: 10.1034/j.1399-6576.1999.430910.x. View

15.

Sivanesan E, Gitlin M, Candiotti K . Opioid-induced Hallucinations: A Review of the Literature, Pathophysiology, Diagnosis, and Treatment. Anesth Analg. 2016; 123(4):836-43. PMC: 6482381. DOI: 10.1213/ANE.0000000000001417. View

16.

Walker P, Palla S, Pei B, Kaur G, Zhang K, Hanohano J . Switching from methadone to a different opioid: what is the equianalgesic dose ratio?. J Palliat Med. 2008; 11(8):1103-8. PMC: 2982711. DOI: 10.1089/jpm.2007.0285. View

17.

Lotsch J . Opioid metabolites. J Pain Symptom Manage. 2005; 29(5 Suppl):S10-24. DOI: 10.1016/j.jpainsymman.2005.01.004. View

18.

Mercadante S, Bruera E . Opioid switching: a systematic and critical review. Cancer Treat Rev. 2006; 32(4):304-15. DOI: 10.1016/j.ctrv.2006.03.001. View

19.

MacDonald N, Der L, Allan S, Champion P . Opioid hyperexcitability: the application of alternate opioid therapy. Pain. 1993; 53(3):353-355. DOI: 10.1016/0304-3959(93)90232-E. View

20.

De La Cruz M, Ransing V, Yennu S, Wu J, Liu D, Reddy A . The Frequency, Characteristics, and Outcomes Among Cancer Patients With Delirium Admitted to an Acute Palliative Care Unit. Oncologist. 2015; 20(12):1425-31. PMC: 4679079. DOI: 10.1634/theoncologist.2015-0115. View